

MammalExpress

Optimizing protein production

PROBLEM

- The production of recombinant proteins in mammalian cells is expensive. We seek to make it cheaper.

MARKET

- Mammalian cell-produced recombinant proteins are widely used in research, biomedicine, cosmetics, cellular agriculture, etc. The current market size is over **€200 billion** and growing fast.

SOLUTION

- MammalExpress creates technology which is easy to add to the existing production pipelines throughout the industry.
- Our solution improves mRNA stability and resulting protein yields by implementing our unique skills in 3'UTR engineering.

COMPETITIVE ADVANTAGE

- Easy to implement
- Currently we can almost double production without changing anything else than the 3'UTR of the expression system.
- No current competitors in the market; we offer a unique, additive, optimization step to conventional protein production pipeline

FUTURE BUSINESS MODEL

- Licensing of our technology
- Providing tailored service to corporates on specified proteins

ACHIEVEMENTS

- €626,000 funding from [Business Finland](#)
- Accepted to:
 - [Spark Finland](#)
 - [Node by Slush](#)
 - [Venture Alliances](#)


SEEKING

- Partnerships with Biotech & Pharma firms for proof-of-concept projects
- Seed funding for 2024 Fall


Conventional approach

Our approach

**Energy
Space
Medium
Workforce
Expensive:**
Reactor:
300.000\$ +
extras




[Website](#) & [Press Release](#)



Project leader
Jaan-Olle Andressoo, UH
Professor
jaan-olle.andressoo@helsinki.fi
rashad@terkko.fi

Team members
Sakari Hietanen, CTO
Rashad Ismayilzada, Head of Commercialization
Vilma Iivanainen, Technical Support
Mehdi Mirzaie, Bioinformatician
Peyman Choopanian, Bioinformatician



Steering group
Dr. Tassos Damdimopoulos, KI
Dr. Marc Baumann, UH
Dr. Lauri Reuter, Nordic Foodtech VC
Dr. Eero Mustalahti, Biovian